SynthesisPloS one2016

Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis.

Xin-Yue Lian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.